Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. - Wikidata - awgldk - TriplyDB

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.

http://www.wikidata.org/entity/Q34487137

about

Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer Radical prostatectomy versus watchful waiting for prostate cancer Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer Optimal duration of androgen deprivation therapy following radiation therapy in intermediate- or high-risk nonmetastatic prostate cancer: A systematic review and metaanalysis Imaging biomarker roadmap for cancer studies Adjuvant medical therapy for prostate cancer.Pilot trial of adjuvant paclitaxel plus androgen deprivation for patients with high-risk prostate cancer after radical prostatectomy: results on toxicity, side effects and quality-of-life.Androgen deprivation therapy for prostate cancer-review of indications in 2010 Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health-related quality of life benefits for osteoporotic men with prostate cancer.Contemporary role of androgen deprivation therapy for prostate cancer Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review Update on the management of prostate cancer with goserelin acetate: patient perspectives Bicalutamide-induced hepatotoxicity: A rare adverse effect.Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years.Bicalutamide-associated fulminant hepatotoxicity.Hormone therapy in the management of prostate cancer: evidence-based approaches Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer An update on the changing indications for androgen deprivation therapy for prostate cancer.Does primary androgen-deprivation therapy delay the receipt of secondary cancer therapy for localized prostate cancer?Management of prostate cancer. Part 2: localized and locally advanced disease.Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States preventative task force report on screening?Optimizing decisions about treatment in locally advanced prostate cancer.Comparison of two adjuvant hormone therapy regimens in patients with high-risk localized prostate cancer after radical prostatectomy: primary results of study CU1005 Adjuvant treatment to surgery.Adjuvant treatment to radiation: combined hormone therapy and external radiotherapy for locally advanced prostate cancer.Use of androgen deprivation therapy in prostate cancer: indications and prevalence.Management of locally advanced prostate cancer Survival following primary androgen deprivation therapy among men with localized prostate cancer Treatment and Mortality in Men with Localized Prostate Cancer: A Population-Based Study in California.The role of radical prostatectomy in high-risk prostate cancer Diagnostic evaluation of PSA recurrence and review of hormonal management after radical prostatectomy.The role of primary androgen deprivation therapy in localized prostate cancer.Additional therapy for high-risk prostate cancer treated with surgery: what is the evidence?The modern role of androgen deprivation therapy in the management of localised and locally advanced prostate cancer.Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence.Contemporary treatment of high-risk localized prostate cancer.Screening, risk assessment, and the approach to therapy in patients with prostate cancer.Pharmacotherapeutic management of locally advanced prostate cancer: current status.The role of surgery in high-risk localised prostate cancer.

P2860

Q24193722-F1CD25F0-0B01-4879-B397-CFB8F6B18165 Q24236564-89E37139-F62C-4885-ACF4-A14732D42B4B Q24244156-37A6BFFA-D33F-48CA-8A8C-E9F303A5E5E1 Q26801000-1ADAA18C-FB45-412F-AD7B-80AF3E1433EF Q30242020-4EB60CAF-18E9-462D-9115-F650A720C214 Q33758771-4CA11B6C-19FF-42AD-859A-6CC8B8299E3A Q33939310-12694DCB-6BDC-44F9-AA6A-58161CACAF58 Q34111603-05E8CB12-1114-407F-A3E1-37F70357952D Q34143921-262A7041-9759-40AB-9ED2-1A0DCCC7E37C Q34211155-4DC7D622-7339-4364-86DD-DD887349C0D5 Q34296202-A3112F2E-F3FA-4BFB-96AB-CBCA3218F75C Q34418403-17913108-3D2A-42E2-89EC-A8A68C7E0614 Q34426599-E122AC4C-B097-4C65-BC60-53D141A8CC97 Q34537714-3D80E960-6CF4-4A4F-B707-A46A1B8D64C5 Q34585070-E55746DA-B78F-4C71-B1A0-2DFB9D063404 Q34801274-C57EC177-2B69-4C6B-9547-6046890B4955 Q35076432-FD9BF8A3-7D51-4069-91B6-D8A5C95B115D Q35079955-350DE223-BD44-4CD3-BE22-21B2F058D57B Q35549863-DF0C439E-2970-44ED-8A20-F6C78BE4F943 Q36319986-4D073DC8-7274-447A-9E57-08E7A8541F13 Q36448693-D7490826-AFA7-4758-9651-132BB417CDD6 Q36520539-85723470-AC49-4C9B-A0F9-E28002E5AB2E Q36842603-5A90766A-F117-45AB-9FD4-EE6EFEE7173D Q36861594-6B0EB91C-6113-4256-94F3-51E8C4EFA269 Q36861768-7781ED22-0ED5-488C-B8CD-D68F92036077 Q36861772-320C1824-2756-4A52-9848-50856FC92273 Q37074379-87218960-51D8-479E-A8B8-CA9373F23741 Q37074747-16B952D4-5A37-43D9-A675-EDDD81215D34 Q37104386-C06085DC-5312-4FF6-B3DC-41EF128CBFA6 Q37134562-DAF86D56-6B9F-4F8D-8E11-3FC4CD5A54FA Q37270502-50999E18-BF76-45E0-98E0-A28782BA0997 Q37399907-C3EB9F87-4C55-4E23-BFD0-A4052D932223 Q37468238-52FE404F-329F-48C4-B9CA-F040622328F1 Q37546041-2E9FA85C-FECC-49E5-8842-036658E95B90 Q37708169-F638F8AE-A89A-4F63-B39F-CA61FBE33CE4 Q37735433-2F90D634-03DE-43A9-860F-740219E42712 Q37774353-DCB2FA71-AA6A-445A-8617-F08972BE30BC Q37801615-D07ED365-7D39-4A52-B8E7-1B1231C040E7 Q37888666-0581233A-DB82-4DAF-A363-746418797FA7 Q37939464-C3E64D45-067C-4A40-9ED2-BA67FF760AB6

P2860

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.

http://www.wikidata.org/entity/Q34487137

description

2006 nî lūn-bûn

@nan

2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.

@ast

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.

@en

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.

@nl

type

label

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.

@ast

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.

@en

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.

@nl

prefLabel

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.

@ast

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.

@en

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.

@nl

P1433

Q34487137-3FA7D8ED-364D-4708-B880-778A57FE1CBC

P1476

Q34487137-8CE01391-57A8-49D0-9001-F6B8F6B6DCED

P2093

Q34487137-1DBDA6FF-7521-417B-AE8C-614852AFFBBF

Q34487137-20E2A971-2061-4ACB-B4E6-92EA0FA59715

Q34487137-4C6EDF98-7FB9-4925-A44C-0B24B2440E4A

Q34487137-60FE126F-6DD5-4854-9225-3AA30014BBE3

Q34487137-B26FF960-ECC4-45FD-BC2F-D7861E1EE033

Q34487137-CCFDDAF1-10E6-48CB-A82D-DC7F4B2CB356

Q34487137-CED7718E-567A-4AC1-96C9-9E3CEEC69356

P2860

Q34487137-0746BCA6-8856-44AF-A51A-5963DE6E0558

Q34487137-17DBFC29-0644-4CDC-8F95-95533E54BCD4

Q34487137-2785F712-942D-4499-B648-90CCB42B0576

Q34487137-374E85F1-22B3-44C7-8E28-D65E93979815

Q34487137-428709A2-048C-4951-89D0-6055AD1B4402

Q34487137-49E5E161-E2E2-4D96-9451-0E247E77CB01

Q34487137-6DAE1893-06BB-4B79-99DE-5348559EF87B

Q34487137-7C00D3F6-CE8F-4288-A645-9C6C89DD5F7E

Q34487137-8154FE75-6947-4AAA-A671-23CD9DC666DE

Q34487137-921B50DD-A0E4-4060-9A64-1CCBAE8D85BB

P304

Q34487137-105F9494-CD75-4AA9-B2B7-EDA1BBEBACFF

P31

Q34487137-3BFECA64-842D-467A-8C2A-CEBE0E3F9522

P356

Q34487137-9FE547A5-B498-4FEB-BD7E-32CE1E4998AD

P433

Q34487137-25670B04-7B7F-485F-954A-61B853284169

P478

Q34487137-C1C3A41D-A2A2-48B3-9FA6-2A19E07526DD

P577

Q34487137-49D39C87-44D9-44B4-BEAC-118D0D3C290E

P698

Q34487137-CB979E6E-0D67-4908-8185-B3AF82B6E01D

P356

J.1464-410X.2005.06051.X

P1433

BJU International

P1476

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.

@en

P2093

Casodex Early Prostate Cancer Trialists' Group

http://www.w3.org/2001/XMLSchema#string

David G McLeod

http://www.w3.org/2001/XMLSchema#string

Jon Armstrong

http://www.w3.org/2001/XMLSchema#string

Manfred P Wirth

http://www.w3.org/2001/XMLSchema#string

Peter Iversen

http://www.w3.org/2001/XMLSchema#string

Thomas Morris

http://www.w3.org/2001/XMLSchema#string

William A See

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment options for early prostate cancer.

Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.

Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.

Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole.

Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experiment.

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

P304

247-254

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1464-410X.2005.06051.X

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P577

2006-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16430622

http://www.w3.org/2001/XMLSchema#string